Scientific Online Resource System

Annual for Hospital Pharmacy

Inhibitors of sodium-glucose linked transporter 2 - A new class antidiabetic drugs used for the treatment of diabetes mellitus type 2

Desimira Mironova, Evgeni Grigorov, Valentina Belcheva, Teodora Handjieva-Darlenska

Abstract

Diabetes mellitus is a chronic disease, declared by the World Health Organization (WHO) as a pandemia, whose growth is progressing daily and affects both economically advanced and developing countries. This fact leads to a number of health, social and economic consequences that need to be surmount, both through measures to prevent and to clarify the pathophysiological mechanisms of the disease and the discovery of new therapeutic approaches for treating hyperglycemia and a decrease in the complications of the underlying disease. With the discovery of selective inhibitors of competitive Sodium-glucose co-transporter-2-inhibitors (abbreviated called SGLT2- inhibitors) begins a new era in the pharmacotherapy of diabetes mellitus type II. In this review are tracked mechanism of action and effects of drugs of that group.

Keywords

Diabetes mellitus; obesity; treatment

Full Text


References

World Health Organization. Global Report on Diabetes.

;978:88. Available from: http://www.who.int/about/licensing http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf

Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med [Internet]. 2006 Nov 28;3(11):e442. Available from: http://dx.doi.org/10.1371%2Fjournal.pmed.0030442

Haslam D. Weight management in obesity - past and present. Int J Clin Pract. 2016 Mar;70(3):206–17.

Valov V, Doneva M, Borisova AM, Tankova T, Czech M, Manova M, et al. Regional differences in diabetic patients’ pharmacotherapy in Bulgaria. Eur Rev Med Pharmacol Sci. 2014;18(10):1499–506.

Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011 Dec;94(3):311–21.

Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct;120(16):1640–5.

Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011 Jun;96(6):1654–63.

ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004 Jan;27 Suppl 1:S5–10.

Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood). 2003 Nov;228(10):1111–7.

Chang G-Y, Park ASD, Susztak K. Tracing the footsteps of glomerular insulin signaling in diabetic kidney disease. Kidney Int [Internet]. 2011 Apr;79(8):802–4. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677185/

Ferris HA, Kahn CR. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest. 2012 Nov;122(11):3854–7.

Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet (London, England). 2003 Jan;361(9353):226–8.

Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011 Apr;13(4):401–12.

Janowska J, Chudek J, Olszanecka-Glinianowicz M, Semik-Grabarczyk E, Zahorska-Markiewicz B. Interdependencies among Selected Pro-Inflammatory Markers of Endothelial Dysfunction, C-Peptide, Anti-Inflammatory Interleukin-10 and Glucose Metabolism Disturbance in Obese Women. Int J Med Sci. 2016;13(7):490–9.

Type 2 diabetes drug discovery and development. Nat Rev Drug Discov [Internet]. 2009 May;8(5):431. Available from: http://dx.doi.org/10.1038/nrd2888

Chao EC, Henry RR. SGLT2 inhibition — a novel strategy for diabetes treatment. Nat Rev Drug Discov [Internet]. 2010 Jul;9(7):551–9. Available from: http://dx.doi.org/10.1038/nrd3180

Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001 Jan;280(1):F10-8.

Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–8.

Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007 Jan;261(1):32–43.

Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci [Internet]. 2011 Feb;32(2):63–71. Available from: http://www.sciencedirect.com/science/article/pii/S0165614710002129

Abdul-Ghani M, DeFronzo R. Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus. Endocr Pract [Internet]. 2008 Sep 1;14(6):782–90. Available from: http://dx.doi.org/10.4158/EP.14.6.782

Poudel R. Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J Endocrinol Metab [Internet]. 2013 Jul 1;17(4):588–93. Available from: http://www.ijem.in/article.asp?issn=2230-8210

Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007 Aug;(106):S27-35.

Röder P V, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H. The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing. PLoS One [Internet]. 2014 Feb 26;9(2):e89977. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0089977

DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012 Jan;14(1):5–14.

Nomura S. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent. Curr Top Med Chem. 2010;10(4):411–8.

Von Mering J. Über künstlichen Diabetes. Cent für die medizinische Wiss. 1886;22:31.

Karamanou M, Protogerou A, Tsoucalas G, Androutsos G, Poulakou-Rebelakou E. Milestones in the history of diabetes mellitus: The main contributors. World J Diabetes [Internet]. 2016 Jan 10;7(1):1–7. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707300/

Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014 Mar;53(3):213–25.

Gangadharan Komala M, Mather A. Empagliflozin for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol. 2014 May;7(3):271–9.

Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014 Oct;16(10):984–93.

Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012 Dec;72(17):2289–312.

Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. Eur J Pharm Sci [Internet]. 2016 Oct 10;93:244–52. Available from: http://www.sciencedirect.com/science/article/pii/S0928098716303141


Refbacks

Article Tools
Email this article (Login required)